普伐他汀对急性冠状动脉综合征患者血浆可溶性CD40配体水平影响的研究

目的观察普伐他汀对急性冠状动脉综合征(ACS)患者血浆可溶性CD40配体(sCD40L)水平的影响。方法选择ACS患者38例,稳定性心绞痛(SAP)患者32例,正常健康体检者40例,采用酶联免疫吸附法(ELISA)测定其血浆可溶性sCD40L浓度,并在入院后立即给予ACS患者及SAP患者服用普伐他汀(20mg/d),8周后复查其血浆可溶性sCD40L。结果ACS患者血浆sCD40L水平高于SAP组及对照组,SAP组与对照组之间无差别;血浆sCD40L水平与血TC、LDL-C呈正相关,与HDL-C呈负相关;普伐他汀治疗8周后ACS患者血浆sCD40L水平下降,而SAP组血浆sCD40L水平无明显改变。结论ACS患者血浆sCD40L水平升高,可能与其发病机制密切相关,血浆sCD40L水平可作为ACS诊断及病情判断的重要指标;普伐他汀能降低ACS患者血浆sCD40L水平,对于ACS的临床治疗有着重要的意义。

An effect study on pravastatin on plasma level of sotuble CD40 ligand in acute coronary syndrome

Objective The article is to investigate the effect of pravastatin on plasma level of soluble CD40 ligand (sCD40L) in acute coronary syndrome (ACS) patients. Method 38 cases of ACS patients, 32 cases of stable angina pectoris (SAP) patients and 40 cases of normal volunteer were chosen. Plasma levels of sCD40L in above patients were detected by ELISA. After the detection, ACS patients and SAP patients were given pravastatin (20 mg/d) for 8 weeks, and then, the levels of sCD40L were detected again. Result The level of sCD40L in ACS patients was higher than that in SAP and normal patients; there was no difference between SAP and normal patients. A positive correlation existed between plasma sCD40L and TC LDL-C, and negative correlation between plasma sCD40L and HDL-C. The level of sCD40L in ACS had declined since pravastatin was administrated. Conclusion Plasm level of sCD40L becoming higher in ACS patients may be related to the pathogenesis of ACS.Pravastatin can reduce plasma level of sCD40L, contributing to treatment of ACS.